CASE STUDY
A Connected Solution for Better Chemo Care ManagementA Patient Support Hub
Using 21st Technology To Detect Early Signs of Febrile Neutropenia (FN) In Chemotherapy Patients.
Of the 60K cancer patients hospitalized each year for FN, 7% die. Improving patients’ outcomes by combining a remote patient monitoring solution with digitally connected services to administer early treatment. Ultimately, offering a unique value-based differentiator for a competitive biosimilar marketplace.
.
The Client
A Top 20 Global Pharmaceutical
Clinical Focus
Cancer Care
Intended Use
Pre-SaMD
The Result
An MVP solution with defined experience pathways, real-world validation and a business model.
Challenge
The Client launched a cancer care biosimilar into a highly competitive marketplace and wanted to use digital health opportunities to offer real differentiation on patient and clinician value.
Approach
- Market sensing: Unmet needs and opportunities
- Experience strategy: Clinical journey mapping and ideation
- Concepting: Solution hypothesis and service concept
- Validation: Research with medical directors, payers, etc.
- Planning: Business case modeling, GTM strategy, pilot partner identification
Solution
The resulting solution was an MVP- Digital eHealth ecosystem, connecting chemo patients with a coordinated care team to reduce hospitalization length of stay and related outcomes, improving patient QoL. The MVP included a solution diagram, solution video, outlined experience pathways, and takeaways from customer interviews.
By The Numbers
Initial Solution Concepts
Hospitalizations for FN annually
60K
Average cost for FN hospitialization
Target Users
Patients given pegfilgrastim for FN
Technology
Targeted: iOS, Android, connected devices, VARA
Markets
United States, EU
Testimonial
I spend a lot of time trying to figure out where my body is at, physically, mentally, physiology…this is taken care of, it’s monitored… That would really be beneficial.